HCAR2 anticorps (AA 200-228)

N° du produit ABIN5536145

Détail du produit anti-HCAR2 anticorps

Antigène: HCAR2 (Hydroxycarboxylic Acid Receptor 2 (HCAR2))

Épitope: AA 200-228

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp HCAR2 est non-conjugé

Application: Western Blotting (WB)

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogène: This NIACR1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 200-228 amino acids from the Central region of human NIACR1.

Isotype: Ig Fraction

Information d'application

Indications d'application: For WB starting dilution is: 1:1000

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.5 mg/mL

Buffer: Supplied in PBS with 0.09 % (W/V) sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Détails sur HCAR2

Antigène: HCAR2 (Hydroxycarboxylic Acid Receptor 2 (HCAR2))

Autre désignation: NIACR1 (HCAR2 Produits)

Synonymes: anticorps GPR109A, anticorps HCA2, anticorps HM74a, anticorps HM74b, anticorps NIACR1, anticorps PUMAG, anticorps Puma-g, anticorps Gpr109a, anticorps Gpr109b, anticorps HM74, anticorps Hcar2, anticorps PUMA-G, anticorps Pumag, anticorps mHM74b, anticorps HCAR2, anticorps HCAR3, anticorps hydroxycarboxylic acid receptor 2, anticorps HCAR2, anticorps Hcar2, anticorps LOC527744

Sujet: NIACR1 acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.

Poids moléculaire: 42 kDa

ID gène: 338442

UniProt: Q8TDS4